Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
Vous n'êtes pas connecté
Vertex (VRTX) is a great stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
CBT is poised for strong growth, driven by robust performance in its business segments on healthy demand.
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
FSI's share price rally is driven by strong Q2 results, upbeat prospects for NanoChem and ENP and expectations of continued robust performance.
DSGX's Q2 fiscal 2025 performance is likely to have gained from robust demand for its differentiated offerings and buyout strategies.
Salesforce (CRM) continued its transformation efforts to provide stronger financial figures after beating Q2 expectations on Wednesday and raising its...
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.